Exchange: EURONEXT Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-0.48% €9.27
America/New_York / 17 mai 2024 @ 11:35
FUNDAMENTALS | |
---|---|
MarketCap: | 1 941.08 mill |
EPS: | -0.200 |
P/E: | -46.35 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 209.39 mill |
Avg Daily Volume: | 0.208 mill |
RATING 2024-05-17 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | ||||
Ebit | n/a | n/a | ||||
Asset | n/a | n/a | n/a | n/a | ||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -46.35 | sector: PE 17.08 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.95x |
Company: PE -46.35 | industry: PE 23.71 |
DISCOUNTED CASH FLOW VALUE |
---|
€27.18 (193.20%) €17.91 |
Date: 2024-05-19 |
Expected Trading Range (DAY) |
---|
€ 9.12 - 9.42 ( +/- 1.60%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | €9.27 (-0.48% ) |
Volume | 0.172 mill |
Avg. Vol. | 0.208 mill |
% of Avg. Vol | 82.66 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.